This study is NOT currently recruiting participants.
Number
000410-I
Sponsoring Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Recruitment Detail
Type: Completed Study; data analyses ongoing Gender: Male & Female Min Age: 18 Years Max Age: 50 Years
Referral Letter Required
No
Population Exclusion(s)
Children
Keywords
Seasonal Influenza; Flu Virus; Respiratory Illness; Viral Infection; Experimental Vaccine
Recruitment Keyword(s)
None
Condition(s)
Influenza; seasonal influenza
Investigational Drug(s)
VRC-FLUMOS0111-00-VP VRC-GENADJ0110-AP-NV
Investigational Device(s)
Intervention(s)
Other: VRC-GENADJ0110-AP-NV Biological/Vaccine: Flucelvax Drug: VRC-FLUMOS0111-00-VP (FluMos-v1)
Supporting Site
National Institute of Allergy and Infectious Diseases
Background:
Influenza (flu) is a contagious respiratory illness. It is caused by influenza viruses that infect the nose, throat, and sometimes the lungs. Vaccines are given to teach the body to prevent or fight infection. Researchers want to study a new vaccine to prevent the seasonal flu.
Objective:
To see if the FluMos-v1 vaccine is safe and how the body responds to it.
Eligibility:
Healthy adults ages 18-50 who received at least one licensed flu vaccine from 2016 through the 2019-2020 influenza season.
Design:
Participants will be screened through a separate protocol.
Participants will be tested for COVID-19. They may have a pregnancy test.
Participants will receive the FluMos-v1 vaccine or the Flucelvax vaccine. It will be injected in the upper arm.
Participants will complete a diary card for 7 days. They will record any symptoms they have. They will be given a thermometer to check their temperature. They will also be given a ruler to measure any skin changes at the injection site.
Participants will have about 10 study visits. They will be asked how they are feeling and if they have taken any medications. They will have blood drawn.
Participants will have oral mucosal samples collected using a thin swab. They may have nose and throat secretions collected using a thin swab.
Some participants will have optional apheresis. Blood will be removed through a needle in a vein in one arm. A machine will separate the white blood cells. The rest of the blood will be returned through a needle in a vein in the other arm.
Participation will last for 40 weeks.
--Back to Top--
INCLUSION CRITERIA: A subject must meet all of the following criteria: 1. Healthy adults between the ages of 18-50 years inclusive 2. Based on history and physical examination, in good general health and without history of any of the conditions listed in the exclusion criteria 3. Part A: Received at least one licensed influenza vaccine from 2016 through the 2019-2020 influenza season 4. Part B and C: Received at least one licensed influenza vaccine from 2017 through the 2022-2023 influenza season 5.Able and willing to complete the informed consent process 6. Available for clinic visits for 40 weeks after enrollment and through an influenza season 7. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process 8. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) <=35 within the 56 days before enrollment Laboratory Criteria within 56 days before enrollment 8. White blood cells (WBC) and differential within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval 9. Total lymphocyte count >=800 cells/microliter 10. Platelets = 125,000 - 500,000 cells/microliter 11. Hemoglobin within institutional normal range or accompanied by the PI or designee approval 12. Alanine aminotransferase (ALT) <=1.25 x institutional upper limit of normal (ULN) 13. Aspartate aminotransferase (AST) <=1.25 x institutional ULN 14. Alkaline phosphatase (ALP) <1.1 x institutional ULN 15. Total bilirubin within institutional normal range or accompanied by the PI or designee approval. 16. Serum creatinine <=1.1 x institutional ULN 17. Negative for HIV infection by an FDA-approved method of detection 18. Negative for SARS-CoV-2 prior to enrollment Criteria applicable to women of childbearing potential: 19. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on the day of enrollment 20. Agrees to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study EXCLUSION CRITERIA: A subject will be excluded if one or more of the following conditions apply: 1. Breast-feeding or planning to become pregnant during the study Subject has received any of the following substances: 2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment 3. Blood products within 16 weeks prior to enrollment 4. Live attenuated vaccines within 4 weeks prior to enrollment 5. Inactivated vaccines within 2 weeks prior to enrollment 6. Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study 7. Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule 8. Current anti-TB prophylaxis or therapy 9. Previous investigational H1, H2, or H10 influenza vaccines, including Part A participants 10. Part A: a. Groups 1A, 2A, and 3A only: Receipt of the 2020-2021 season s licensed influenza vaccine at any time prior to enrollment b. Groups 1B, 2B, and 3B only: Receipt of the 2020-2021 season s licensed influenza vaccine within 4 months prior to enrollment. 11. Part B and C: a. Groups 4A, 5A, 6A, 7A, and 8A only: Receipt of the 2021-2022 or 2022-2023 season s licensed influenza vaccine at any time prior to enrollment b. Groups 4B, 5B, 6B, 7B, and 8B only: Receipt of the 2021-2022 or 2022-2023 season s licensed influenza vaccine within 4 months prior to enrollment. Subject has a history of any of the following clinically significant conditions: 12. Serious reactions to vaccines that preclude receipt of the study vaccination as determined by the investigator 13. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema 14. Asthma that is not well controlled 15. Diabetes mellitus (type I or II), with the exception of gestational diabetes 16. Thyroid disease that is not well controlled 17. Idiopathic urticaria within the past year 18. Autoimmune disease or immunodeficiency 19. Hypertension that is not well controlled 20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws 21. Malignancy that is active or history of malignancy that is likely to recur during the period of the study 22. Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years 23. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen 24. Guillain-Barre Syndrome 25. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject s ability to give informed consent.
A subject must meet all of the following criteria:
1. Healthy adults between the ages of 18-50 years inclusive
2. Based on history and physical examination, in good general health and without history of any of the conditions listed in the exclusion criteria
3. Part A: Received at least one licensed influenza vaccine from 2016 through the 2019-2020 influenza season
4. Part B and C: Received at least one licensed influenza vaccine from 2017 through the 2022-2023 influenza season
5.Able and willing to complete the informed consent process
6. Available for clinic visits for 40 weeks after enrollment and through an influenza season
7. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
8. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) <=35 within the 56 days before enrollment
Laboratory Criteria within 56 days before enrollment
8. White blood cells (WBC) and differential within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval
9. Total lymphocyte count >=800 cells/microliter
10. Platelets = 125,000 - 500,000 cells/microliter
11. Hemoglobin within institutional normal range or accompanied by the PI or designee approval
12. Alanine aminotransferase (ALT) <=1.25 x institutional upper limit of normal (ULN)
13. Aspartate aminotransferase (AST) <=1.25 x institutional ULN
14. Alkaline phosphatase (ALP) <1.1 x institutional ULN
15. Total bilirubin within institutional normal range or accompanied by the PI or designee approval.
16. Serum creatinine <=1.1 x institutional ULN
17. Negative for HIV infection by an FDA-approved method of detection
18. Negative for SARS-CoV-2 prior to enrollment
Criteria applicable to women of childbearing potential:
19. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on the day of enrollment
20. Agrees to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study
EXCLUSION CRITERIA:
A subject will be excluded if one or more of the following conditions apply:
1. Breast-feeding or planning to become pregnant during the study
Subject has received any of the following substances:
2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment
3. Blood products within 16 weeks prior to enrollment
4. Live attenuated vaccines within 4 weeks prior to enrollment
5. Inactivated vaccines within 2 weeks prior to enrollment
6. Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study
7. Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule
8. Current anti-TB prophylaxis or therapy
9. Previous investigational H1, H2, or H10 influenza vaccines, including Part A participants
10. Part A:
a. Groups 1A, 2A, and 3A only: Receipt of the 2020-2021 season s licensed influenza vaccine at any time prior to enrollment
b. Groups 1B, 2B, and 3B only: Receipt of the 2020-2021 season s licensed influenza vaccine within 4 months prior to enrollment.
11. Part B and C:
a. Groups 4A, 5A, 6A, 7A, and 8A only: Receipt of the 2021-2022 or 2022-2023 season s licensed influenza vaccine at any time prior to enrollment
b. Groups 4B, 5B, 6B, 7B, and 8B only: Receipt of the 2021-2022 or 2022-2023 season s licensed influenza vaccine within 4 months prior to enrollment.
Subject has a history of any of the following clinically significant conditions:
12. Serious reactions to vaccines that preclude receipt of the study vaccination as determined by the investigator
13. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema
14. Asthma that is not well controlled
15. Diabetes mellitus (type I or II), with the exception of gestational diabetes
16. Thyroid disease that is not well controlled
17. Idiopathic urticaria within the past year
18. Autoimmune disease or immunodeficiency
19. Hypertension that is not well controlled
20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
21. Malignancy that is active or history of malignancy that is likely to recur during the period of the study
22. Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years
23. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen
24. Guillain-Barre Syndrome
25. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject s ability to give informed consent.
Principal Investigator
Referral Contact
For more information: